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important and primary process in SSc pathogenesis [3] [4] [5] . In fact, the dysregulation of vascular tone control, which manifests clinically as Raynaud's phenomenon, and microcirculatory abnormalities are the earliest clinical manifestations of SSc, and may precede the onset of fibrosis by months or years [3] [4] [5] . The vascular damage in SSc affects primarily the microvasculature (small and medium-sized arteries, arterioles and capillaries) and can be observed in all affected organs [3, 4] . Increasing evidence suggests that microvascular endothelial cell (MVEC) injury and apoptosis occur early in SSc, and that progressive proliferation of the intima leads to vessel narrowing and obliteration [4, [6] [7] [8] [9] [10] . In the very early phase, increased vascular permeability favours plasma and mononuclear cell extravasation, with formation of perivascular inflammatory infiltrates, clinically represented by oedema of the fingers (puffy hands) [5] . The involvement of microvessels causes recurrent episodes of ischemia-reperfusion injury and reduces capillary blood flow leading to a state of chronic tissue ischemia, lack of nutrients and severe tissue hypoxia, thus contributing to organ dysfunction and significant morbidity and mortality [3] [4] [5] . [3, [10] [11] [12] [13] [14] . [5, [15] [16] [17] (see Fig. 1 ). These specific capillaroscopic changes are also referred as 'scleroderma pattern' and differentiate SSc from primary Raynaud's phenomenon, in which usually capillaries are normal in number and size [15] . [4, 6, 18, 19] [20, 21] .
With disease progression, vessels lose their elasticity, the vessel media and adventitia become fibrotic, and occlusion of the small arteries, together with platelet activation and aggregation, facilitates thrombotic events with severe organ complications, such as digital ulceration or amputation, pulmonary arterial hypertension, and scleroderma renal crisis

The disarray of the microcirculation is testified by the extensive morphological modifications detected by nailfold capillaroscopy. The capillaroscopic features are enlarged, giant and bushy capillaries, microhaemorrhages and, in particular, a variable loss of capillaries with formation of avascular areas (vascular desertification)
The abnormal capillary morphology followed by the loss of capillaries is the clear evidence of the disturbance of the angiogenic process that does not allow the regeneration of functional microvessels. This may be seen as a paradox because usually tissue hypoxia stimulates angiogenesis with the formation of new capillaries from pre-existing vessels. However, despite the increase of vascular endothelial growth factor (VEGF) and others pro-angiogenic molecules in SSc skin and serum, the disease evolves towards a progressive loss of capillaries
. In the past, it had been thought that impaired angiogenesis and increased apoptosis of mature ECs were exclusively responsible for the microvascular abnormalities in SSc. However, several studies published over the last few years suggest that an impairment of vasculogenesis and vascular repair may be also involved in SSc capillary loss, with altered numbers and functional defects of circulating endothelial progenitor cells (EPCs), as well as abnormalities in the commitment of bone marrow-derived mesenchymal stem cells (MSCs) towards the EC lineage
This review presents current knowledge of mechanisms of defective vascular repair in SSc and discusses the role that abnormalities in the angiogenic and vasculogenic processes may play in the pathophysiology of SSc. We also discuss how the angiogenic and vasculogenic processes might be manipulated to develop novel vascular treatment strategies for this complex disease.
Angiogenesis and vasculogenesis
Angiogenesis is a complex and finely balanced process that consists in the formation of new vessels from the pre-existing ones such as capillaries and post-capillary venules, and plays a pivotal role during embryonal development and later, in adult life, in several physiological and pathological conditions, such as corpus luteum formation, tumours and chronic inflammation [22, 23] [24, 25] . In contrast, pathological angiogenesis is mainly linked to an imbalance between pro-angiogenic and anti-angiogenic mediators [23] . The major pro-angiogenic and anti-angiogenic factors are listed in Table 1 In SSc, the production of vasoactive molecules is dysregulated following EC perturbation [49] . In the early stage of SSc, activated ECs highly express vascular adhesion molecules, which enable the transmigration of inflammatory and immune cells through the endothelium leading to the formation of perivascular inflammatory infiltrates [50] [51] [52] [53] [54] . This results in a complex perivascular cellular reaction involving injured ECs, immune and inflammatory cells, and fibroblasts that become constitutively activated and transdifferentiate into myofibroblasts [1, 55] . Altered secretion of vasodilators and vasoconstrictors, and chronic activation of platelets and fibrinolytic pathways secondary to EC activation are also found [49, 56, 57] 
Mechanisms of defective angiogenesis in SSc
Clinical and in vitro evidence indicate an impaired angiogenic response in SSc [6] . Comparative immunohistological studies of SSc and normal skin biopsies have shown that SSc involved skin has significantly fewer dermal capillaries [31, 65] . In vitro studies demonstrated that serum from SSc patients is toxic for ECs and may inhibit EC migration and vascular tube formation [66] .
During the pro-angiogenic switch, both the innate and adaptive immune cells are involved in the mechanisms of EC activation, proliferation and migration through the production and release of a large spectrum of pro-angiogenic mediators [67] . In this regard, numerous in vitro studies on peripheral blood mononuclear cells suggest a defective contribution of SSc immune cells to angiogenesis. Impaired angiogenic activity has been reported in peripheral blood lymphocytes and monocytes from SSc patients [68, 69] . Furthermore, supernatants from SSc peripheral blood mononuclear cells decreased EC chemotaxis [70] , and SSc serum failed to enhance normal mononuclear cell angiogenic capacity [71] . In contrast, another study reported that a subset of mononuclear cells from SSc patients displays enhanced angiogenic activity [72] .
Increasing evidence also suggests a severe imbalance between pro-angiogenic and anti-angiogenic factors [6] [73] . [6, 19, 50, 62, [74] [75] [76] [77] VEGF is one of the major regulators of angiogenesis [78] . [19, 79, 80] [19, 79] . In agreement with these findings, a number of studies demonstrated that serum levels of VEGF are significantly increased in SSc patients throughout different disease stages and correlate with organ manifestations [52, 74, 77, 81, 82] . Another recent study showed an altered expression of VEGF, PlGF and VEGF receptors which was associated with decidual and villous vasculopathy in placental tissue from pregnancies in women with SSc [83] . [78, 84] [3, 17] . Therefore, the uncontrolled and chronic overexpression of VEGF found in SSc might lead to the formation of a chaotic capillary network rather than promote the formation of new functional and stable capillaries [19] . Moreover, in SSc skin Konttinen and coworkers [65] [85] . [19, 86] [66, 74, 77, [87] [88] [89] [90] (Fig. 1) . Endostatin, an endogenous angiogenesis inhibitor derived from the breakdown of type XVIII collagen, is increased in SSc serum and associates with the presence of more severe clinical involvement [74, 77, 87, 89] . A recent study showed that plasmin activity is reduced while the amount of circulating angiostatin, a cleavage product of plasminogen, is increased in SSc plasma [66] . Furthermore, normal human MVECs exhibited reduced migration and proliferation when exposed to SSc plasma, as well as a significant impaired ability to form vascular structures in collagen after exposure to angiostatin in amounts similar to those detected in SSc plasma [66] .
Up-regulated pro-angiogenic factors in SSc include: VEGF, platelet-derived growth factor (PDGF), transforming growth factor-␤1 (TGF-␤1), fibroblast growth factor-2 (FGF-2), placental growth factor (PlGF), ET-1, monocyte chemoattractant protein-1 (MCP-1), stromal cell-derived factor-1 (SDF-1/CXCL12), tumour necrosis factor-␣ (TNF-␣), interleukin (IL)-8, fractalkine/CX3CL1, and vascular adhesion molecules E-selectin, P-selectin and their soluble forms
Several studies have shown that VEGF expression is markedly increased in different cell types both in the epidermis and dermis of patients with SSc
. VEGF exerts its biological functions by binding to the tyrosine kinase receptors VEGFR-1 (flt-1) and VEGFR-2 (flk-1/KDR), which both are up-regulated on dermal ECs in SSc affected skin
Sufficient tissue vascularization depends on the tight regulation of the expression of VEGF and its receptors
Because the expression of VEGF is stimulated by hypoxia, in SSc one would expect that chronic hypoxia could even contribute to persistent overexpression of VEGF, that is one of the main transcriptional targets of hypoxia-inducible factor (HIF)-1␣ [86]. However, HIF-1␣ protein expression was not increased and did not correlate with up-regulated VEGF in the skin of SSc patients
There is also evidence that platelets may be key players in the profound imbalance between pro-angiogenic and angiostatic factors in SSc. In fact, human platelets carry in their alpha granules a set of angiogenesis stimulators, such as VEGF, FGF-2, PDGF and TGF-␤1, and inhibitors, such as endostatin, platelet factor-4 and thrombospondin-1 [91] . Moreover, these angiogenesis-regulatory molecules are sequestered in platelets in higher concentration than in plasma, and are packed into separate and distinct alpha granules and differentially released after platelet activation [91, 92] . Many reports document evidence in SSc for ongoing platelet activation, aggregation and release of bioactive molecules into the circulation and in injured endothelium [56, 57] . A recent study has shown that SSc platelets store and transport high levels of VEGF [93] . Therefore, platelets may be a source of circulating VEGF in the course of SSc because of their activation at the contact of injured endothelium, possibly contributing to impaired angiogenesis [93] 
. In particular, the angiogenesis inhibitor pentraxin-3 (PTX3), which is known to inhibit the proangiogenic effects of FGF-2, was strongly up-regulated in SSc
MVECs compared with control MVECs [95] . Instead, several genes that promote cell migration and adhesion to the extracellular matrix were down-regulated in SSc MVECs, suggesting an antiinvasive phenotype of these cells [95] . [105] (Fig. 2) . [109] . 
In fact, MVECs can perform angiogenesis only when provided with a proper enzymatic machinery, enabling them to lyse the extracellular matrix and invade the surrounding tissue. In this regard, the cell-associated plasminogen activator system is known to play a crucial role in angiogenesis by modulating the adhesive properties of ECs in their interactions with the extracellular matrix and in the degradation of matrix components [100, 101]. The urokinase-type plasminogen activator (uPA) promotes growth, chemotaxis and matrix invasion of ECs by interaction with its receptor, uPAR, which is constitutively expressed on ECs [102]. uPAR not only functions as uPA receptor, but also plays an important role in cell motility and adhesion through its binding interactions with vitronectin and intracellular signalling mediators, such as the integrin receptors [103]. A recent in vitro study has shown that in dermal MVECs isolated from SSc skin, uPAR undergoes truncation between domains 1 and 2, a cleavage that is known to impair uPAR functions [85]. The uPAR cleavage occurring in SSc MVECs was associated with the overexpression of MMP-12 [85]. Indeed, overproduction of MMP-12 by SSc dermal MVECs and fibroblasts accounted for endothelial uPAR cleavage leading to impaired uPA-induced EC migration, invasion, proliferation, and capillary morphogenesis on Matrigel [85, 104] (Fig. 2). Interestingly, treatment with an anti-MMP-12 monoclonal antibody was able to restore the angiogenic activity of MVECs, including cell migration, chemoinvasion and tube formation [85, 105]. Furthermore, the same authors have shown that in SSc MVECs uPAR cleavage results in loss of an integrin-mediated uPAR connection with the actin cytoskeleton [105]. The uncoupling of cleaved uPAR from ␤2 integrins impaired the activation of the small Rho GTPases Rac and Cdc42, thus inhibiting their mediation of uPAR-dependent cytoskeletal rearrangement and cell motility, and ultimately blocked the integrin-engagementdelivered signals to the actin cytoskeleton resulting in loss of angiogenesis
In another recent study, the expression of the CXC chemokine SDF-1 and its receptor CXCR4 was investigated in the skin and dermal MVECs isolated from SSc patients [76]. The SDF-1/CXCR4 axis regulates specific steps in new vessel formation. SDF-1 released by or expressed on ECs creates a local chemokine gradient, dictating directional responses of ECs expressing CXCR4 [106]. Moreover, SDF-1-CXCR4 interaction further amplifies angiogenesis by increasing VEGF release by ECs [107]. SDF-1 is also a strong chemoattractant for CXCR4-expressing EPCs which are mobilized from the bone marrow in response to tissue ischemia [108]. The expression of SDF-1 and CXCR4 is elevated in capillaries of lesional skin and MVECs from early stage SSc, suggesting a role in the pathogenesis of SSc microvascular abnormalities [76]. Interestingly, it has also been shown that a functional gene polymorphism which affects SDF-1 gene expression is associated with major SSc vascular manifestations, such as pulmonary arterial hypertension and ischemic digital ulcers
Mechanisms of defective vasculogenesis in SSc
Besides impaired angiogenesis, there is evidence that defective vasculogenesis may contribute to the vascular pathophysiology of SSc [20] 
Fig. 2 MMP-12-dependent cleavage of uPAR in SSc microvascular endothelial cells (MVECs) results in impaired angiogenesis. uPAR is a glycosylphosphatidylinositol-anchored 3-extracellular domain (D1-D2-D3) cell surface receptor that concentrates the serine protease activity of the uPA in the pericellular region and promotes extracellular matrix remodelling. The main binding site for uPA is located in D1, and interaction of uPA and uPAR activates the proteolytic cascade necessary to open a path within tissues to migrating cells. Moreover, uPAR not only functions as uPA receptor but also plays a role in growth factor activation, cell adhesion, differentiation, proliferation and migration by interacting with extracellular matrix molecules, including vitronectin (VN), and intracellular signalling mediators, such as the integrin receptors. VN/uPAR interaction occurs directly with D1, but requires the integrity of the full-length receptor (D1-D2-D3). The removal of D1 also abolishes the interaction of uPAR with integrins and its ability to regulate the integrin adhesive functions. The constitutive overproduction and secretion of MMP-12 by SSc dermal MVECs and fibroblasts accounts for endothelial cell uPAR cleavage between D1 and D2, leaving a truncated receptor (D2-D3) on MVEC surface which results in loss of an integrin-mediated uPAR connection with the actin cytoskeleton. The uncoupling of cleaved uPAR from integrins impairs the activation of Rac and Cdc42, thus inhibiting their ability to bind the p21-activated protein kinase 1 (PAK-1), which regulates the downstream signalling cascades of small Rho GTPases and the uPARdependent cytoskeletal rearrangement. The net result is the impairment of cell proliferation, migration, invasion, and tube formation, thus preventing SSc MVECs from entering a suitable angiogenic programme in vitro. See text for abbreviations.
score displayed lower circulating EPC counts, suggesting increased homing to peripheral ischemic tissues and consequent EPC depletion in the blood at this disease stage [116] . In addition, the levels of late-outgrowth EPCs were not different between SSc patients and healthy individuals, as determined by the in vitro colony-forming assay [116] .
Altogether, the conflicting data on EPCs suggest that different scenarios might be responsible for the vascular repair defect in SSc (Fig. 3) . In fact, the findings of decreased EPC levels regardless of SSc stage [113] could suggest that EPC depletion might occur within the bone marrow and/or early after their mobilization into the circulation (Fig. 3) . Alternatively, the findings of increased EPC levels in early/active stage and subsequent reduction with disease progression and severity [64, 114, 116] could suggest that EPCs might be mobilized from the bone marrow and home to ischemic tissues, where they might fail to repair vascular damage due to intrinsic functional defects. Moreover, persistent peripheral endothelial injury and ischemia-reperfusion episodes might eventually lead to depletion of EPCs in the peripheral circulation (Fig. 3) .
In this regard, two recent studies have suggested that the bone marrow microenvironment for stem cells is impaired in SSc [21, 117] [122] . Obviously, mimicking such complicated series of events is difficult to achieve in human beings using conventional drug-delivery systems, which generally function via a burst-release mechanism. However, several release systems are being successfully established [122] [123] [124] 
